Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Functional RNAi Screens Define Distinct Protein Kinase Vulnerabilities in EGFR-Dependent HNSCC Cell Lines.

Hinz TK, Kleczko EK, Singleton KR, Calhoun J, Marek LA, Kim J, Tan AC, Heasley LE.

Mol Pharmacol. 2019 Sep 25. pii: mol.119.117804. doi: 10.1124/mol.119.117804. [Epub ahead of print]

2.

ALK is a critical regulator of the MYC-signaling axis in ALK positive lung cancer.

Pilling AB, Kim J, Estrada-Bernal A, Zhou Q, Le AT, Singleton KR, Heasley LE, Tan AC, DeGregori J, Doebele RC.

Oncotarget. 2018 Jan 16;9(10):8823-8835. doi: 10.18632/oncotarget.24260. eCollection 2018 Feb 6.

3.

Melanoma Therapeutic Strategies that Select against Resistance by Exploiting MYC-Driven Evolutionary Convergence.

Singleton KR, Crawford L, Tsui E, Manchester HE, Maertens O, Liu X, Liberti MV, Magpusao AN, Stein EM, Tingley JP, Frederick DT, Boland GM, Flaherty KT, McCall SJ, Krepler C, Sproesser K, Herlyn M, Adams DJ, Locasale JW, Cichowski K, Mukherjee S, Wood KC.

Cell Rep. 2017 Dec 5;21(10):2796-2812. doi: 10.1016/j.celrep.2017.11.022.

4.

Analysis of Drug Resistance Using Kinome-Wide Functional Screens.

Singleton KR, Earley KT, Heasley LE.

Methods Mol Biol. 2017;1636:163-177. doi: 10.1007/978-1-4939-7154-1_11.

PMID:
28730479
5.
6.

Kinome RNAi Screens Reveal Synergistic Targeting of MTOR and FGFR1 Pathways for Treatment of Lung Cancer and HNSCC.

Singleton KR, Hinz TK, Kleczko EK, Marek LA, Kwak J, Harp T, Kim J, Tan AC, Heasley LE.

Cancer Res. 2015 Oct 15;75(20):4398-406. doi: 10.1158/0008-5472.CAN-15-0509. Epub 2015 Sep 10.

7.

An Inducible TGF-β2-TGFβR Pathway Modulates the Sensitivity of HNSCC Cells to Tyrosine Kinase Inhibitors Targeting Dominant Receptor Tyrosine Kinases.

Kleczko EK, Kim J, Keysar SB, Heasley LR, Eagles JR, Simon M, Marshall ME, Singleton KR, Jimeno A, Tan AC, Heasley LE.

PLoS One. 2015 May 6;10(5):e0123600. doi: 10.1371/journal.pone.0123600. eCollection 2015.

8.

Systematic identification of signaling pathways with potential to confer anticancer drug resistance.

Martz CA, Ottina KA, Singleton KR, Jasper JS, Wardell SE, Peraza-Penton A, Anderson GR, Winter PS, Wang T, Alley HM, Kwong LN, Cooper ZA, Tetzlaff M, Chen PL, Rathmell JC, Flaherty KT, Wargo JA, McDonnell DP, Sabatini DM, Wood KC.

Sci Signal. 2014 Dec 23;7(357):ra121. doi: 10.1126/scisignal.aaa1877.

9.

Bioinformatics-driven discovery of rational combination for overcoming EGFR-mutant lung cancer resistance to EGFR therapy.

Kim J, Vasu VT, Mishra R, Singleton KR, Yoo M, Leach SM, Farias-Hesson E, Mason RJ, Kang J, Ramamoorthy P, Kern JA, Heasley LE, Finigan JH, Tan AC.

Bioinformatics. 2014 Sep 1;30(17):2393-8. doi: 10.1093/bioinformatics/btu323. Epub 2014 May 7.

10.

A mechanism of resistance to gefitinib mediated by cellular reprogramming and the acquisition of an FGF2-FGFR1 autocrine growth loop.

Ware KE, Hinz TK, Kleczko E, Singleton KR, Marek LA, Helfrich BA, Cummings CT, Graham DK, Astling D, Tan AC, Heasley LE.

Oncogenesis. 2013 Mar 25;2:e39. doi: 10.1038/oncsis.2013.4.

11.
12.

Fibroblast growth factor receptors are components of autocrine signaling networks in head and neck squamous cell carcinoma cells.

Marshall ME, Hinz TK, Kono SA, Singleton KR, Bichon B, Ware KE, Marek L, Frederick BA, Raben D, Heasley LE.

Clin Cancer Res. 2011 Aug 1;17(15):5016-25. doi: 10.1158/1078-0432.CCR-11-0050. Epub 2011 Jun 14.

13.

Elevated extracellular K+ inhibits apoptosis of corneal epithelial cells exposed to UV-B radiation.

Singleton KR, Will DS, Schotanus MP, Haarsma LD, Koetje LR, Bardolph SL, Ubels JL.

Exp Eye Res. 2009 Aug;89(2):140-51. doi: 10.1016/j.exer.2009.02.023. Epub 2009 Mar 14.

PMID:
19289117
14.

Effect of triplet repeat expansion on chromatin structure and expression of DMPK and neighboring genes, SIX5 and DMWD, in myotonic dystrophy.

Frisch R, Singleton KR, Moses PA, Gonzalez IL, Carango P, Marks HG, Funanage VL.

Mol Genet Metab. 2001 Sep-Oct;74(1-2):281-91.

PMID:
11592825

Supplemental Content

Loading ...
Support Center